Stephanie Harvard
Cited by
Cited by
HIV/AIDS in Vancouver, British Columbia: a growing epidemic
CW McInnes, E Druyts, SS Harvard, M Gilbert, MW Tyndall, VD Lima, ...
Harm Reduction Journal 6 (1), 1-5, 2009
Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups
CA Marra, LD Lynd, SS Harvard, M Grubisic
BMC health services research 11 (1), 1-7, 2011
Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia
C Panessa, WD Hill, E Giles, A Yu, S Harvard, G Butt, A Andonov, ...
Journal of Viral Hepatitis 16 (1), 64-73, 2009
Randomized controlled trial evaluating pictogram augmentation of HIV medication information
K Wilby, CA Marra, JH da Silva, M Grubisic, S Harvard, LD Lynd
Annals of Pharmacotherapy 45 (11), 1378-1383, 2011
Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation-an economic analysis based on the ESPOIR cohort
K Chevreul, G Haour, S Lucier, S Harvard, ML Laroche, X Mariette, ...
PLoS One 9 (5), e97077, 2014
Consumer preferences for food allergen labeling
CA Marra, S Harvard, M Grubisic, J Galo, A Clarke, S Elliott, LD Lynd
Allergy, Asthma & Clinical Immunology 13 (1), 1-11, 2017
Mortality is influenced by locality in a major HIV/AIDS epidemic
EF Druyts, BS Rachlis, VD Lima, SS Harvard, W Zhang, EK Brandson, ...
HIV medicine 10 (5), 274-281, 2009
Social, ethical, and other value judgments in health economics modelling
S Harvard, GR Werker, DS Silva
Social Science & Medicine 253, 112975, 2020
Ontario’s plunging price-caps on generics: deeper dives may drown some drugs
A Anis, S Harvard, C Marra
Open Medicine 5 (3), e149, 2011
Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort
S Harvard, D Guh, N Bansback, P Richette, M Dougados, A Anis, ...
RMD open 2 (1), e000230, 2016
More than just needles: An evidence-informed approach to enhancing harm reduction supply distribution in British Columbia
JA Buxton, EC Preston, S Mak, S Harvard, J Barley
Harm Reduction Journal 5 (1), 1-7, 2008
Harm reduction product distribution in British Columbia
SS Harvard, WD Hill, JA Buxton
Canadian journal of public health 99 (6), 446-450, 2008
Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies
S Harvard, L Gossec, T Pham, P Richette, M Dougados, A Anis, B Fautrel
Joint bone spine 83 (1), 101-103, 2016
Canadian policy on food allergen labelling: consumers’ perspectives regarding unment needs
KM Brown, NE Fenton, LD Lynd, CA Marra, JM FitzGerald, SS Harvard, ...
Univers J Public Health 3, 41-48, 2015
Value judgments in a COVID-19 vaccination model: A case study in the need for public involvement in health-oriented modelling
S Harvard, E Winsberg, J Symons, A Adibi
Social Science & Medicine 286, 114323, 2021
Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib
CA Marra, LD Lynd, L Colley, SS Harvard, D Lacaille, E Schwenger, ...
The Journal of Rheumatology 39 (5), 910-915, 2012
The epistemic risk in representation
S Harvard, E Winsberg
Kennedy Institute of Ethics Journal 32 (1), 2022
Health Economists on involving patients in modeling: potential benefits, harms, and variables of interest
S Harvard, GR Werker
Pharmacoeconomics 39 (7), 823-833, 2021
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
S Harvard, D Guh, N Bansback, P Richette, A Saraux, B Fautrel, A Anis
Cost Effectiveness and Resource Allocation 15 (1), 1-13, 2017
Purposes and duties in scientific modelling
E Winsberg, S Harvard
J Epidemiol Community Health, 2022
The system can't perform the operation now. Try again later.
Articles 1–20